Table 7.
Salvage therapy details for EBRT studies.
| First author/ country | Year | Single-centre (1) or Multi-centre (2) | Patients (n) | Treatment Technique | Delivery System | Dose (total dose (Gy)/ dose per fraction/ number of fractions) | Whole or Partial Gland/ Focal | Duration of treatment | Adjuvant ADT | Follow-up (mo) (range) | BC (%) | Oncologic outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fuller (USA) | 2020 | 2 | 50 | SBRT | Cyberknife | 34 / 6.8 / 5 | Whole | 5 days | Yes (14%) | 44 (3-110) | 60 | 2-yr bRFS 76%, 5-yr bRFS 60% |
| Cuccia (Italy) | 2020 | 1 | 24 | SBRT | VMAT | 30/06/05 | Whole | 5-12 days | Yes (16.7%) | 21 (2-68) | 54.9 | 1-yr bRFS 80%, 2-yr bRFS 54.9%, OS 100% |
| Matrone (Italy) | 2020 | 1 | 44 | SBRT | VMAT | 35 / 5 / 7 | Focal | 7 days | Yes (27%) | 25.4 (6.7-81.5) | 59 | 1-yr bRFS 85.9%, 2-yr bRFS 58.3%, 2-yr LC 90.1%, 2-yr OS 100% |
| Caroli (Italy) | 2020 | 1 | 38 | SBRT | NR | 18/ 6/ 3 | Focal | 3 days | NR | 27 (4-35) | NR | bRFS 15 months |
| Bergamin (Australia) | 2020 | 1 | 25 | SBRT | VMAT | 36 / 6 / 6 (72%) vs 38/ 6.3/ 6 (28%) | Focal | 14 days | Yes (48%) | 25 (13-46) | 80 | 2-yr bRFS 80% |
| D'Agostino (Italy) | 2019 | 1 | 23 | SBRT | VMAT | 25/ 5/ 5 | Whole | 5 days | Yes (43.5%) | 33 (5-58) | 34.8 | 2-yr bRFS 41.7%, 2-yr LC 61.1%, OS 100% |
| Pasquier (France) | 2019 | 2 | 100 | SBRT | Cyberknife (81%)/ VERO-IMRT, RapidArc | 36 / 6 / 5 | 49% Whole vs 51% Partial | 12 days | Yes (36%) | 29.3 (4-91) | NR | bRFS 48 months, 3-yr bRFS 55%, 4-yr OS 94% |
| Scher (France) | 2019 | 1 | 42 | SBRT | Cyberknife | 36 / 6 / 6 | Focal | NR | Yes (19%) | 21 (3-31) | 94 | median PFS 11 months, LC 100% |
| Jereczek-Fossa (Italy) | 2018 | 1 | 64 | SBRT | Cyberknife/ VERO-IMRT | 30/ 6/ 5 | Whole | 5 days | Yes (25%) | 26.1 (3.1-82.4) | 64 | 2-yr bRFS 40%, LC 75%, OS 92% |
| Loi (Italy) | 2018 | 1 | 50 | SBRT | Cyberknife | 30/ 6/ 5 | NR | 5 days | Yes (30%) | 21.3 (6.1-49.2) | 60 | 1-yr bRFS 80%, 1-yr mFS 92% |
| Leroy (France) | 2017 | 1 | 23 | SBRT | Cyberknife | 36 / 6 / 6 | 83% Whole vs 17% Partial | 14 days | Yes (61%) | 22.6 (6-40) | 54 | 2-yr bRFS 54%, OS 100%, 2-yr local dFS 76% |
SBRT, Stereotactic body radiotherapy; VMAT, Volumetric modulated arc therapy; IMRT, Intensity-modulated radiation therapy; Gy, grey; ADT, androgen deprivation therapy; mo, months; BC, biochemical control; bRFS, biochemical recurrence free survival; mFS, metastasis free survival; RFS, relapse free survival; CSS, cancer specific survival; OS, overall survival; PFS, progression free survival.